Browsing: Clinical Trials & R&D

Alveus obesity drug secures $160M to advance into Phase 2 testing, targeting amylin and GLP-1 pathways.

Alumis TYK2 psoriasis drug shows promise with Phase 3 results, doubling shares and competing with Takeda and Johnson & Johnson.

Merck ADC trial hold affects small cell lung cancer study, with FDA citing higher than anticipated deaths.

Galapagos TYK2 drug GLPG3667 succeeds in dermatomyositis trial but misses in lupus study, impacting future partnerships.

Peanut allergy patch shows positive results in Phase 3 study, paving way for 2026 FDA submission.

Nektar autoimmune drug shows promise in alopecia study, despite missing statistical success, supporting late-stage testing.

Argenx halts two Vyvgart trials for thyroid eye disease after interim results show ineffectiveness, impacting potential market expansion.

Sanofi Tolebrutinib setback includes a Phase 3 failure in primary progressive MS and a delayed US approval decision.

Arcus Gilead trial cancellation marks a setback in cancer research as the TIGIT/PD-1 study is halted for futility, impacting future strategies.

Lilly retatrutide obesity drug demonstrates up to 29% weight loss in Phase 3 study, setting a new benchmark for competitors.